Ella Mendelson
Overview
Explore the profile of Ella Mendelson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
218
Citations
4435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, et al.
Clin Microbiol Infect
. 2023 Mar;
29(7):918-923.
PMID: 36921715
Objectives: The capability of the SARS-CoV-2 Omicron variant to escape immunity conferred by mRNA vaccines has led to the development of Omicron-adapted vaccines. In this study, we aimed to compare...
12.
Weil M, Sofer D, Shulman L, Weiss L, Levi N, Aguvaev I, et al.
Sci Total Environ
. 2023 Feb;
871:161985.
PMID: 36739034
Israel conducts routine environmental (15 sites) and acute flaccid paralysis (AFP) surveillance for poliovirus. During September 2021, increasing numbers of wastewater samples collected from more than one site in the...
13.
Jurkowicz M, Nemet I, Atari N, Fratty I, Kliker L, Sherbany H, et al.
J Med Virol
. 2023 Jan;
95(2):e28498.
PMID: 36653733
Community surveillance found the 2019-2020 A(H1N1)pdm09 predominant influenza season in Israel to be a high-intensity season with an early and steep morbidity peak. To further characterize disease severity in the...
14.
Shulman L, Laassri M, Handsher R, Zagorodnyaya T, Sofer D, Weil M, et al.
Vaccines (Basel)
. 2022 Dec;
10(12).
PMID: 36560563
Background: Poliovirus post-eradication containment of wild-type 2 poliovirus (PV2) requires the destruction of all materials containing, or potentially containing, PV2. Acute flaccid paralysis (AFP) cases in Israel between 1973 and...
15.
Canetti M, Barda N, Gilboa M, Indenbaum V, Mandelboim M, Gonen T, et al.
Nat Commun
. 2022 Dec;
13(1):7711.
PMID: 36513665
Booster doses for the ongoing COVID-19 pandemic are under consideration in many countries. We report a three-month follow-up of 700 participants in a fourth vaccine dose study, comparing BNT162b2 and...
16.
Barda N, Canetti M, Gilboa M, Asraf K, Indenboim V, Weiss-Ottolenghi Y, et al.
Clin Infect Dis
. 2022 Nov;
76(7):1315-1317.
PMID: 36366729
The correlation between anti-severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre-fourth dose levels using data from 1098 healthcare workers....
17.
Canetti M, Barda N, Gilboa M, Indenbaum V, Asraf K, Gonen T, et al.
N Engl J Med
. 2022 Nov;
387(22):2092-2094.
PMID: 36351266
No abstract available.
18.
Atari N, Kliker L, Zuckerman N, Elkader B, Weiss-Ottolenghi Y, Mendelson E, et al.
Euro Surveill
. 2022 Nov;
27(44).
PMID: 36330820
We evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.5 and BA.2.75) in fully vaccinated (three doses of Comirnaty vaccine) healthcare workers (HCW)...
19.
Bassal R, Keinan-Boker L, Cohen D, Mendelson E, Lustig Y, Indenbaum V
Vaccines (Basel)
. 2022 Oct;
10(10).
PMID: 36298527
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Israel in February 2020 and spread from then. In December 2020, the FDA approved an emergency use authorization of the Pfizer-BioNTech...
20.
Barda N, Canetti M, Gilboa M, Indenboim V, Asraf K, Weiss-Ottolenghi Y, et al.
Euro Surveill
. 2022 Sep;
27(39).
PMID: 36177870
We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97)...